ES2743701T3 - Conjugados de ligando-fármaco del receptor sigma-2 como compuestos antitumorales, métodos de síntesis y usos de los mismos - Google Patents

Conjugados de ligando-fármaco del receptor sigma-2 como compuestos antitumorales, métodos de síntesis y usos de los mismos Download PDF

Info

Publication number
ES2743701T3
ES2743701T3 ES15773524T ES15773524T ES2743701T3 ES 2743701 T3 ES2743701 T3 ES 2743701T3 ES 15773524 T ES15773524 T ES 15773524T ES 15773524 T ES15773524 T ES 15773524T ES 2743701 T3 ES2743701 T3 ES 2743701T3
Authority
ES
Spain
Prior art keywords
cancer
compounds
compound
erastin
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15773524T
Other languages
English (en)
Spanish (es)
Inventor
William Hawkins
Robert Mach
Dirk Spitzer
Suwanna Vangveravong
Tine Brian Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Washington University in St. Louis
Original Assignee
University of Washington
Washington University in St. Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St. Louis filed Critical University of Washington
Application granted granted Critical
Publication of ES2743701T3 publication Critical patent/ES2743701T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES15773524T 2014-04-01 2015-04-01 Conjugados de ligando-fármaco del receptor sigma-2 como compuestos antitumorales, métodos de síntesis y usos de los mismos Active ES2743701T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973366P 2014-04-01 2014-04-01
PCT/US2015/023954 WO2015153814A1 (en) 2014-04-01 2015-04-01 Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof

Publications (1)

Publication Number Publication Date
ES2743701T3 true ES2743701T3 (es) 2020-02-20

Family

ID=54241267

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15773524T Active ES2743701T3 (es) 2014-04-01 2015-04-01 Conjugados de ligando-fármaco del receptor sigma-2 como compuestos antitumorales, métodos de síntesis y usos de los mismos

Country Status (8)

Country Link
US (5) US10087175B2 (enExample)
EP (1) EP3126356B1 (enExample)
JP (1) JP6557253B2 (enExample)
CN (1) CN106459011B (enExample)
AU (2) AU2015240775B2 (enExample)
CA (1) CA2944069C (enExample)
ES (1) ES2743701T3 (enExample)
WO (1) WO2015153814A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944069C (en) 2014-04-01 2022-03-08 William Hawkins Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
US11175296B2 (en) * 2016-10-26 2021-11-16 Washington University Methods of diagnosing and treating cancer comprising ME1
WO2018218087A1 (en) * 2017-05-24 2018-11-29 K-Gen, Inc. Methods of cancer treatment
WO2019113004A1 (en) * 2017-12-04 2019-06-13 Memorial Sloan Kettering Cancer Center Methods of cancer treatment via regulated ferroptosis
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
US20070161644A1 (en) 2005-01-25 2007-07-12 Stockwell Brent R Erastin analogs and uses thereof
WO2006081337A2 (en) * 2005-01-25 2006-08-03 Whitehead Institute For Biomedical Research Erastin analogues and their uses for killing cancer cells
BRPI0607306A2 (pt) 2005-01-25 2009-08-25 Prolexys Pharmaceuticals Inc derivados de quinoxalina como agentes anti-tumor
WO2006130426A2 (en) * 2005-05-27 2006-12-07 Kemia, Inc. Modulators of ccr-5 activity
JP2009521484A (ja) 2005-12-22 2009-06-04 プロレキシーズ ファーマシューティカルズ インコーポレイテッド ３−アリール置換キナゾロンおよびその使用
WO2008013987A2 (en) * 2006-07-27 2008-01-31 Prolexys Pharmaceuticals, Inc. N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
US8324251B2 (en) 2006-10-04 2012-12-04 Bristol-Myers Squibb Company Cyclic modulators of chemokine receptor activity
US8143222B2 (en) 2007-10-22 2012-03-27 Washington University Modular platform for targeted therapeutic delivery
CA2944069C (en) 2014-04-01 2022-03-08 William Hawkins Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof

Also Published As

Publication number Publication date
AU2019200353A1 (en) 2019-02-07
AU2019200353B2 (en) 2020-01-30
CA2944069A1 (en) 2015-10-08
JP2017509672A (ja) 2017-04-06
US10975069B2 (en) 2021-04-13
AU2015240775B2 (en) 2019-01-03
US10087175B2 (en) 2018-10-02
US20190002457A1 (en) 2019-01-03
JP6557253B2 (ja) 2019-08-07
CN106459011A8 (zh) 2017-06-30
CN106459011B (zh) 2019-11-15
EP3126356A4 (en) 2017-08-16
US20210221805A1 (en) 2021-07-22
US20170015660A1 (en) 2017-01-19
EP3126356A1 (en) 2017-02-08
AU2015240775A1 (en) 2016-10-20
CA2944069C (en) 2022-03-08
WO2015153814A1 (en) 2015-10-08
CN106459011A (zh) 2017-02-22
EP3126356B1 (en) 2019-07-31
US20250145617A1 (en) 2025-05-08
US10344029B2 (en) 2019-07-09
NZ724819A (en) 2020-09-25
US20200123149A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
ES2981592T3 (es) Derivados de 6-(4-amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3H)-ona y compuestos relacionados como inhibidores de PTPN11 (SHP2) para tratar el cáncer
JP7696443B2 (ja) Ｅｇｆｒ変異を有するがんを処置するためのアミノ置換ヘテロ環類
US20250145617A1 (en) Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
ES2981114T3 (es) 8-ciano-5-piperidino-quinolinas como antagonistas de TLR7/8 y sus usos para el tratamiento de trastornos inmunitarios
ES2808988T3 (es) Composiciones y métodos para inhibir la actividad arginasa
ES2881395T3 (es) Composiciones y métodos para inhibir la actividad de la arginasa
ES2805232T3 (es) Compuestos y composiciones para inhibir la actividad de SHP2
ES2858753T3 (es) Derivados de 6-oxo-N-(1-(bencil)-1H-pirazol-4-il)-6,7,8,9-tetrahidropirido[3&#39;,2&#39;:4,5]pirrolo[1,2-a]pirazin-2-carboxamida como inhibidores de cinasa S6 ribosómica (RSK) p90 para el tratamiento del cáncer
ES2810852T3 (es) Compuestos y composiciones para inhibir la actividad de shp2
ES2950764T3 (es) Compuestos y composiciones para tratar trastornos hematológicos
KR20230049678A (ko) 이카로스 또는 아이올로스에 의해 매개되는 장애를 위한 유리한 요법
ES2447295T3 (es) Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
ES2691411T3 (es) Uso de bloqueadores de los canales de sodio para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia
WO2025096738A1 (en) Kras inhibitors
JP2024523839A (ja) 突然変異体ｂｒａｆを分解する療法薬
ES2988261T3 (es) Formas mórficas de GIT38 y métodos de fabricación de las mismas
WO2018005533A1 (en) Antiproliferative pyrimidine-based compounds
ES3002745T3 (en) Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
CN110730664A (zh) 含谷氨酰胺酶抑制剂的组合疗法
ES3041367T3 (en) Eaat2 activators and methods of using thereof
BRPI0715566A2 (pt) composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto
ES2928666T3 (es) Piridinetionas, sus composiciones farmacéuticas y su uso terapéutico para el tratamiento de enfermedades proliferativas, inflamatorias, neurodegenerativas o inmunomediadas
ES2390801T3 (es) Procedimiento para el tratamiento de la neoplasia con una combinación de agentes quimioterápicos y radiación